Last reviewed · How we verify

NCT06715696

The Hemostatic Effectiveness of "HANBIO" Gauze During Non-emergent Gynecology Surgery.

Completed NA Last updated 29 May 2025
What this trial tests

NA trial testing "HANBIO" Gauze (Sterilized, 1% Collagen) in Wounds and Injuries in 40 participants. Completed in 31 March 2025.

Timeline
15 December 2024
Primary endpoint
31 March 2025
31 March 2025

Quick facts

Lead sponsorHAN Biomedical Inc
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposesupportive care
Enrollment40
Start date15 December 2024
Primary completion31 March 2025
Estimated completion31 March 2025
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

HAN Biomedical Inc

Who can join

Adults 20 to 70, female only, with Wounds and Injuries or Hemostasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to collect the hemostatic effectiveness and device safety data of "HANBIO" Gauze in subjects have acute wound result from gynecology surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Wounds and Injuries

Currently open trials in the same condition.

Other HAN Biomedical Inc trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06715696.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing